Perelman School of Medicine Events Calendar

The University of Pennsylvania, Center for Bioethics Colloquium Series, featuring Dan Brock, PhD, Frances Glessner Lee Professor of Medical Ethics, Department of Global Health & Social Medicine, Harvard Medical School
Title: TBD

This event is free and open to the public

 

Christopher B. Newgard, PhD

Duke University

 

 March 20, 2012

 

4:00 PM

 

Translational Research Center, 12th Floor

Conference Room 12-146

 

http://www.med.upenn.edu/idom/

For this workshop BPP invites individuals from different parts of the industry community such as HR and recruitment specialist, presidents of start-up companies, directors of large pharmaceutical companies as well as smaller biotechnology industry companies. They will explain what is needed to get into this field, what you should expect, the pro’s and con’s, and what you will be able to gain.

Associate Professor of Medicine
Division of Hematology/Oncology Cancer Biology
Perelman School of Medicine at the University of Pennsylvania
 
"Cancer inflammation and immunoediting: is there a paradox for T cells in pancreatic cancer?"

 

Guatemala Health Initiative: Reports from the field

 

 

Presented by Jare Melanie Philip, Janet Sung,

Ollin Venegas, and Vanessa Ramirez

 

 

 

Jare Melanie Philip, Janet Sung, Ollin Venegas, and Vanessa Ramirez will describe results from their research conducted in Santiago Atitlan during summer 2011.

 

They will explore help seeking among pregnant mothers, midwifery in the context of a rapidly modernizing culture, decision making among mothers with young children and men’s perceptions of health and sport.

 

 

When:        Tuesday, March 20, 2012

Time:         5:00 pm – 6:30 pm

Where:      Irvine Auditorium-3401 Spruce Street

Room:         (IRVINE-G16)

RSVP:        By no later than 12:00 pm Monday, March 19^th to

                  Diana Brown diana.brown@uphs.upenn.edu

"Comparison of Futility Monitoring Methods Using Oncology Trials"
Ed Zhang, Ph.D, American College of Radiology

Abstract: Futility monitoring is an important component in the conduct of clinical trials. An optimal rule would allow timely stopping if the new therapy is harmful or is unlikely to ultimately prove effective. Common methods proposed for futility monitoring include boundaries based on conditional power (CP), repeated confidence intervals (RCIs, adjusted for multiple looks), testing alternative hypothesis with small alpha (0.0025), and the linear 20% inefficacy boundary (LIB20). To compare among these futility rules and relative to no futility monitoring, we will select oncology trials conducted by NCI cooperative groups, include RTOG, National Surgical Adjuvant Breast and Bowel Project (NSABP), and GOG since 1990. These include multiple disease sites and cancer types with time to event as primary endpoints. Total sample size and information for each trial are calculated using protocol specified effect size, type I, and type II error rates. Interim test statistics are reconstructed for each of the proposed futility analysis schedules. Operating characteristics of the futility monitoring rules under each analysis schedules are compared with respect to study duration and sample size, with impact of each rule (summarized as percent savings relative to no futility monitoring) on information, sample size, and calendar time scales over all trials. Preliminary results show that testing alternative hypothesis and RCI rules yield less savings comparing to other rules. The CP10% rule is similar to LIB20 rule with respect to trial duration for more than 3 interim analyses, but saves less on information and sample size scales. The CP30% rule is too aggressive, stopping even when there is clinically meaningful treatment effect.